Table 3.

Association of time-updated incident AF with risk of subsequent cardiovascular events and death after adjustment for potential mediators among adults with CKD

Cardiovascular EventsAdjusted ModelaAdjusted Modela Plus Adjustment for Warfarin and Antiplatelet Agent UseAdjusted Modela Plus Adjustment for Baseline hs-CRP, NT-proBNP, hsTnT, and FGF23 LevelsAdjusted Modela Plus Adjustment for ECG Measures: LVM, LVEF, and LA Diameter
HR (95% CI)HR (95% CI)HR (95% CI)
HF
 No incident AFRefRefRefRef
 Incident AF5.17 (3.89–6.87)5.17 (3.89–6.88)4.91 (3.68–6.56)4.54 (3.23–6.39)
Acute MI
 No incident AFRefRefRefRef
 Incident AF3.64 (2.50–5.31)3.65 (2.50–5.34)3.60 (2.47–5.26)3.05 (1.94–4.78)
Stroke
 No incident AFRefRefRefRef
 Incident AF2.66 (1.50–4.74)2.57 (1.44–4.61)2.71 (1.52–4.84)1.86 (0.91–3.77)
Death
 No incident AFRefRefRefRef
 Incident AF3.30 (2.65–4.12)3.28 (2.63–4.09)3.14 (2.51–3.93)3.12 (2.36–4.11)
Composite outcome of HF, acute MI, stroke, and death
 No incident AFRefRefRefRef
 Incident AF3.68 (2.99–4.53)3.69 (2.99–4.55)3.45 (2.79–4.26)3.40 (2.64–4.38)
  • LVM, left ventricular mass; LVEF, left ventricular ejection fraction; LA, left atrial; Ref, reference value.

  • a Adjusted for age, sex, race/ethnicity, clinical site, diabetes, hypertension, any history of CVD, tobacco use, systolic BP, BMI, eGFR, proteinuria, BMI, LDL cholesterol, HDL cholesterol, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, , β-blocker use, and diuretic use.